Skip to main content
Premium Trial:

Request an Annual Quote

Roche, PerkinElmer Partner on NimbleGen CGX Sales

NEW YORK (GenomeWeb News) – PerkinElmer will sell, service, and provide support for Roche's NimbleGen CGX microarray workflow for most countries outside the US under a supply agreement deal announced today by the two companies.

Roche will continue to sell the workflow in the US and other select markets under the terms of the deal, which takes effect in January.

The NimbleGen CGX array workflow is for the discovery and anlaysis of copy number variations associated with constitutional disorders for the cytogenetics research market and consists of NimbleGen CGX microarrays, reagent kits, the NimbleGen Hybridization Systems, and software for data analysis from Signature Genomics, which PerkinElmer acquired last year.

The NimbleGen CGX array design was developed by Signature Genomics based on an analysis of more than 50,000 cytogenteic samples "to ensure appropriate coverage of the cytogenetically relevant regions," Roche and PerkinElmer said.

Financial and other terms of the deal were not disclosed.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.